BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle

Human Cell

Volumn 24, Issue 4, 2011, Pages 150-160

  Wan, Qian ^a   Liu, Zhibin ^a   Peng, Wenzhen ^a   Wang, Jianmei ^a   Li, Xufeng ^a   Yang, Yi ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

BnRCH; E3 ubiquitin protein ligases; G2 cell cycle arrest; The anti cancer chemotherapeutic drug cisplatin; Transfection

Indexed keywords

CISPLATIN; PROTEIN P21; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAPESEED; TRANSCRIPTION REGULATION; UPREGULATION; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRASSICA NAPUS; CELL LINE, TUMOR; CISPLATIN; FEMALE; G2 PHASE; HELA CELLS; HUMANS; MOLECULAR TARGETED THERAPY; PLANT PROTEINS; TRANSFECTION; UBIQUITIN-PROTEIN LIGASES;

EID: 83455259445     PISSN: 09147470     EISSN: 17490774     Source Type: Journal    
DOI: 10.1007/s13577-011-0036-x     Document Type: Article

References (61)

1. Anfinsen CB, Steinberg D, Vaughan M. Kinetic aspects of assembly and degradation of proteins. Science. 1956; 124: 389-95.
2. Segal HL, Matsuzawa T, Haider M, Abramham GJ. What determines the half-life of proteins in vivo? Some experiences with alanine aminotransferase of rat tissues. Biochem Biophys Res Commun. 1969; 36: 764-70.
3. Etlinger JD, Goldberg AL. A soluble ATP dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci USA. 1977; 74: 54-8.
4. Hershko A, Ciechanover A, Heller H, Rose IA. Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci USA. 1980; 77: 1783-6.
5. Rock KL, Goldberg AL. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999; 17: 739-79.
6. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000; 19: 1473-6.
7. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997; 420: 25-7.
8. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387: 296-9.
9. Hu S, Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem. 2003; 278: 10055-60.
10. MacFarlane M, Merrison W, Bratton SB, Cohen GM. Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem. 2002; 277: 36611-6.
11. Suzuki Y, Nakabayashi Y, Takahashi R. Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death. Proc Natl Acad Sci USA. 2001; 98: 8662-7.
12. Morizane Y, Honda R, Fukami K, Yasuda H. X-linked inhibitor of apoptosis functions as ubiquitin ligase toward mature caspase-9 and cytosolic Smac/DIABLO. J Biochem. 2005; 137: 125-32.
13. Wei D, Sun Y. Small RING finger proteins RBX1 and RBX2 of SCF E3 ubiquitin ligases: the role in cancer and as cancer targets. Genes Cancer. 2010; 1: 700-7.
14. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998; 95: 7987-92.
15. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxiainducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000; 19: 4298-309.
16. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003; 15: 345-50.
17. Lorick KL, Jensen JP, Fang S, Ong AM, Hatakeyama S, Weissman AM. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci USA. 1999; 96: 11364-9.
18. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H, et al. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem. 1999; 274: 31707-12.
19. Lee PS, Wang Y, Dominguez MG, Yeung YG, Murphy MA, Bowtell DDL, et al. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 1999; 18: 3616-28.
20. Miyake S, Lupher ML, Druker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the plateletderived growth factor receptor alpha. Proc Natl Acad Sci USA. 1998; 95: 7927-32.
21. Won KA, Reed SI. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 1996; 15: 4182-93.
22. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev. 1996; 10: 1979-90.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63.
24. Czyzyk-Krzeska MF, Meller J. von Hippel-Lindau tumor suppressor: not only HIF's executioner. Trends Mol Med. 2004; 10: 146-9.
25. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003; 3: 23-34.
26. Starita LM, Parvin JD. The multiple nuclear functions of BRCA1: transcription, ubiquitination and DNA repair. Curr Opin Cell Biol. 2003; 15: 345-50.
27. Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, et al. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem. 2010; 285: 32596-605.
28. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008; 8: 83-93.
29. Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educ. 2006; 83: 724-8.
30. Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222: 385-6.
31. Stordal B, Pavlakis N, Davey R. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev. 2007; 33: 688-703.
32. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001; 478: 23-43.
33. Cubeddu LX, Hoffmann IS, Fuenmayo NT, Finn AL. Efficacy of ondansetron (Gr 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990; 322: 810-6.
34. Aapro MS, Alberts DS. Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med. 1981; 305: 520-6.
35. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C, et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 2000; 158: 85-91.
36. Liu E, Wu J, Cao W, Zhang J, Liu W, Jiang X, et al. Curcumin induces G2/M cell arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neuro-oncol. 2007; 85: 263-70.
37. Chinni SR, Li YW, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell arrest and apoptosis in prostate cancer cells. Oncogene. 2001; 20: 2927-36.
38. Fimognari C, Nüsse M, Cesari R, Iori R, Cantelli-Forti G, Hrelia P. Growth inhibition, cell-cycle arrest and apoptosis in human T-cell leukemia by the isothiocyanate sulforaphane. Carcinogenesis. 2002; 23: 581-6.
39. Schulz S, Klann RC, Schönfeld S, Nyce JW. Mechanisms of cell growth inhibition and cell arrest in human colonie adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res. 1992; 52: 1372-6.
40. Enomoto M, Tsuchida A, Miyazawa K, Yokoyama T, Kawakita H, Tokita H, et al. Vitamin K2-induced cell growth inhibition via autophagy formation in cholangiocellular carcinoma cell lines. Int J Mol Med. 2007; 20: 801-8.
41. Waf1/Cip1. Am J Biochem Biotechnol. 2006; 2: 33-40.
42. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995; 55: 5187-90.
43. Li TM, Chen GW, Su CC, Lin JG, Yeh CC, Cheng KC, et al. Ellagic acid induced p53/p21 expression, G1 arrest and apoptosis in human bladder cancer T24 cells. Anticancer Res. 2005; 25: 971-9.
44. McGrath-Morrow SA, Stahl JL. G1 phase growth arrest and induction of p21Waf1/Cip1/Sdi1 in IB3-1 cells treated with 4-sodium phenylbutyrate. J Pharmacol Exp Ther. 2000; 294: 941-7.
45. Cayrol C, Knibiehler M, Ducommuna B. p21 binding to PCNA causes G1 and G2 cell arrest in p53-deficient cells. Oncogene. 1998; 16: 311-20.
46. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 1998; 282: 1497-501.
47. waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene. 1998; 16: 431-41.
48. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116: 205-19.
49. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007; 26: 1324-37.
50. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, et al. p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev. 1995; 9: 935-44.
51. Lanni JS, Jacks T. Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. Mol Cell Biol. 1998; 18: 1055-64.
52. Linke SP, Clarkin KC, Leonardo AD, Tsou A, Wahl GM. A reversible p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detactable DNA damage. Genes Dev. 1996; 10: 934-47.
53. Kennett SB, Udvadia AJ, Horowitz JM. Sp3 encodes multiple proteins that differ in their capability to simulate or repress transcription. Nucleic Acids Res. 1997; 25: 3110-7.
54. WAF1/CIP1. Nature. 1997; 389: 187-90.
55. Li JM, Datto M, Shen X, Hu P, Yu Y, Wang XF. Sp1, but not Sp3 functions to mediate promotes activation by TGF-β through canonical Sp1 binding sites. Nucleic Acids Res. 1998; 26: 2449-56.
56. Cip1/WAF1 in keratinocyte differentiation. J Biol Chem. 1997; 272: 1308-14.
57. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, et al. Butyrate activated the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem. 1997; 272: 22199-206.
58. Lee SJ, Ha MJ, Lee J, Nguyen PM, Choi YH, Pirnia F, et al. Inhibition of the 3-hyroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-indepenedent transcriptional regulation of p21 (WAF1/CIP1) in human prostate carcinoma cells. J Biol Chem. 1998; 273: 10618-23.
59. WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. Oncogene. 1996; 13: 2047-54.
60. Mohanty S, Huang J, Basu A. Enhancement of cisplatin sensitivity of cisplatin-resistant human cervical carcinoma cells by bryostatin. Clin Cancer Res. 2005; 11: 6730-7.
61. Wu J, Hu CP, Gu QH, Li YP, Song M. Trichostatin A sensitizes cisplatin-resistant A549 cells to apoptosis by up-regulating death-associated protein kinase. Acta Pharmacol Sin. 2010; 31: 93-101.